- Home
- CAPN vs IMRX Comparison
CAPN vs IMRX Comparison
Compare CAPN & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPN
- IMRX
- Stock Information
- Founded
- CAPN 2024
- IMRX 2008
- Country
- CAPN United States
- IMRX United States
- Employees
- CAPN N/A
- IMRX N/A
- Industry
- CAPN
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CAPN
- IMRX Health Care
- Exchange
- CAPN NYSE
- IMRX Nasdaq
- Market Cap
- CAPN 78.3M
- IMRX 73.2M
- IPO Year
- CAPN 2024
- IMRX 2021
- Fundamental
- Price
- CAPN N/A
- IMRX $1.69
- Analyst Decision
- CAPN
- IMRX Buy
- Analyst Count
- CAPN 0
- IMRX 7
- Target Price
- CAPN N/A
- IMRX $12.80
- AVG Volume (30 Days)
- CAPN 7.0
- IMRX 801.9K
- Earning Date
- CAPN 01-01-0001
- IMRX 11-13-2024
- Dividend Yield
- CAPN N/A
- IMRX N/A
- EPS Growth
- CAPN N/A
- IMRX N/A
- EPS
- CAPN N/A
- IMRX N/A
- Revenue
- CAPN N/A
- IMRX N/A
- Revenue This Year
- CAPN N/A
- IMRX N/A
- Revenue Next Year
- CAPN N/A
- IMRX N/A
- P/E Ratio
- CAPN N/A
- IMRX N/A
- Revenue Growth
- CAPN N/A
- IMRX N/A
- 52 Week Low
- CAPN $9.95
- IMRX $1.00
- 52 Week High
- CAPN $10.14
- IMRX $8.07
- Technical
- Relative Strength Index (RSI)
- CAPN N/A
- IMRX 37.40
- Support Level
- CAPN N/A
- IMRX $1.52
- Resistance Level
- CAPN N/A
- IMRX $1.93
- Average True Range (ATR)
- CAPN 0.00
- IMRX 0.19
- MACD
- CAPN 0.00
- IMRX -0.05
- Stochastic Oscillator
- CAPN 0.00
- IMRX 21.95
About CAPN CAYSON ACQUISITION CORP
Cayson Acquisition Corp is a blank check company.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.